1 Adult renal tubular organoids can be produced from different human individuals in a

2 completely same protocol

- 3 Makiko Mori^{1#}, Yutaro Mori^{1#*}, Nakao Yuki¹, Shintaro Mandai¹, Tamami Fujiki¹, Hiroaki
- 4 Kikuchi¹, Fumiaki Ando¹, Koichiro Susa¹, Takayasu Mori¹, Yuma Waseda², Soichiro Yoshida²,
- 5 Yasuhisa Fujii², Eisei Sohara¹, Shinichi Uchida¹
- ⁶ ¹Department of Nephrology and ²Department of Urology, Graduate School of Medical and Dental
- 7 Sciences, Tokyo Medical and Dental University, Tokyo 113-8510, Japan.
- 8 [#]These authors contributed equally to this work.
- 9

10 Lead contact and Corresponding author:

- 11 Yutaro Mori, MD, PhD
- 12 Department of Nephrology
- 13 Graduate School of Medical and Dental Sciences
- 14 Tokyo Medical and Dental University
- 15 1-5-45, Yushima, Bunkyo-ku, Tokyo 113-8510, Japan
- 16 Phone: +81-3-5803-5214; Fax: +81-3-5803-5215; Email: <u>y-mori.kid@tmd.ac.jp</u>

17 Abstract

Introduction: Organoids are miniature organs produced by newly emerging technologies. Kidney organoids originated from human inducible pluripotent stem cells (iPSCs) were developed to recapitulate renal diseases. However, producing iPSC kidney organoids from multiple individuals at the same time and in a uniform condition is still impossible. Here, we report adult renal tubular organoids, "tubuloids", established from primary renal epithelial cells from multiple human individuals in a uniform manner.

Methods: Kidneys obtained from patients due to the surgery for malignancy were minced into small pieces, and primary renal epithelial tubule cells are cultured. 4 patients had normal kidney function and 4 had mild chronic kidney disease (CKD). Growth factors were added to the primary cultured cells at the same time and Matrigel was added to these 8 lines.

28 Results: Primary cultured renal epithelial cells from normal kidneys showed a large number of 29 fine, swollen epithelial appearance. On the other hand, primary cultured kidney epithelial cells 30 from mild CKD kidneys were smaller and slightly elongated than those of normal kidneys. The 31 growth speed was faster in normal kidney cells than in mild CKD cells. At the beginning of the 32 three-dimensionalization (day 0), normal renal tubuloids grew faster than mild CKD tubuloids. 33 The difference in size between normal tubuloids and mild CKD ones became less noticeable on 34 day 5. Both types of tubuloids reached almost same size on day 10. All 8 strains are of different 35 human origin, and uniform tubuloids could be produced at the same time and in a uniform protocol. 36 Conclusion: In terms of pathological models, the differences between mouse models and humans 37 cannot be ignored, and there is a great need for a more human-like model of human pathology 38 from both medical and research perspectives. Our renal tubular organoids can be produced in a

- 39 uniform manner at the same time. It is expected to be used as a new type of convenient human
- 40 pathological model.
- 41
- 42 Key words
- 43 organoids, tubuloids, pathological model, chronic kidney disease

44 Introduction

45 Biomedical engineering has made remarkable progress in recent years, and multiple diseases of 46 various organs have been elucidated by using organoids which are miniature organ-like structures 47 produced by newly emerging technologies and serve as an alternative and more human-like 48 pathological model [1, 2]. Chronic kidney disease (CKD) is an irreversible, progressive disease 49 characterized by glomerular sclerosis, tubular atrophy and collapse, and fibrosis and infiltration of 50 inflammatory cells in the stromal cells [3]. However, the pathogenesis of CKD is not yet fully 51 understood. No curative therapy has been developed as well. There is a great need to understand 52 CKD from both research and medical perspectives.

53 One of the reasons for the delay in CKD research may be the fact that kidney disease is 54 largely influenced by aging [4]. Rats and mice are mainly used for recapitulating kidney diseases. 55 However, they cannot accurately reflect the aging of human organs that are over 80 years old. 56 Kidney organoids established from human inducible pluripotent stem cells (iPSCs) have emerged 57 as a new pathological model to replace rodents [5, 6]. At the present, however, iPSC kidney 58 organoids have not been succeeded to reproducing kidney condition later than the embryonic stage 59 [7]. It is difficult to reflect the aging and senescence process. Another problem with iPSC kidney 60 organoids is that they require extremely skilled technique to fabricate them.

When focusing on pathophysiology of CKD, the most serious problem of iPSC kidney organoids is that they cannot be created from different individuals in a completely uniform manner. To make iPSC kidney organoids, we need to start to establish nephron progenitor cells (NPCs) from iPSCs [5, 6]. Culture condition especially for inducing differentiation into NPCs varies greatly depending on the origin of the iPSCs. Furthermore, NPCs do not necessarily become kidney organoids under the uniform differentiation induction conditions on different strains. This

67 matter that iPSCs from different individuals cannot form kidney organoids with a uniform 68 condition is a critical and fatal weakness for studying CKD having a very large diversity of causes, 69 age, race, sex, and speed of progression. This problem makes accurate analyses of CKD and drug 70 testing for uniform conditions almost impossible. As long as we know, iPSC kidney organoids 71 produced from multiple human-derived iPSCs in a uniform condition has not yet been reported. In 72 addition, even mouse models recapitulating CKD-like diseases have not succeeded in reproducing 73 the diversity that each individual human has which was mentioned above.

Recently, CKD has been considered to be a disease headed by the renal tubules more than the glomerulus [8, 9]. We have focused on renal proximal tubules and have successfully developed tubular organoids derived from primary human renal proximal tubular epithelial cells (hRPTECs) [10-12]. In this study, we have succeeded to produce human adult renal tubular organoids, "tubuloids", from different individuals at the same time in a uniform condition. Our strategy can provide a new insight to analyze pathophysiology of kidney diseases including CKD in a personalized or semi-personalized fashion.

81

82 Methods

Cell culture experiments. Human kidney samples were obtained from kidneys clinically removed from patients with renal cell carcinoma or urothelial malignancy at Tokyo Medical and Dental University Hospital. The protocol was approved by the Institutional Review Board of the Ethics Committee of Tokyo Medical and Dental University (M2022-005). Then, primary hRPTECs were cultured from non-infiltrated areas of the kidney by malignancy, removed as described above.

First, human kidney cortex was cut into small pieces and dissolved in a solution of collagenase type II (1.0 mg/mL) (Worthington Biochemical, NJ, USA). Then, Bovine Serum

90	Albumin (Nacalai Tesque, Kyoto, Japan), Antibiotic-Antifungal (ThermoFisher Scientific, MA,
91	USA), hydrocortisone (ThermoFisher Scientific, MA, USA), ITS liquid media supplement
92	(Sigma-Aldrich, MO, USA), and human recombinant epidermal growth factor (EGF)
93	(ThermoFisher Scientific, MA, USA) in hRPTEC culture medium (DMEM/F-12 (Nacalai Tesque,
94	Kyoto, Japan). Cells were then cultured in a CO2 incubator (5% CO2) at 37°C for 5~7 days.
95	
96	Human renal tubuloid. hRPTECs were seeded on ultra-low adhesion plates using Advanced
97	RPMI 1640 medium with 5% fetal bovine serum (SERANA, Brandenburg, Germany). Two days
98	later, Matrigel (Corning, NY, USA) was added, followed by the addition of Advanced RPMI with
99	5% FBS plus EGF, FGF (ThermoFisher Scientific, MA, USA), and HGF (ThermoFisher Scientific,
100	MA, USA). We define these media containing growth factors above as "tubuloid media". 1~2
101	weeks of incubation in a CO2 incubator (5% CO2) at 37°C completed the tubuloids. The medium
102	was changed about twice a week. No other work was required; basically, they should be left alone.
103	
104	Microscope observation. We observed and took pictures of all the cells and the tubuloids by using
105	BZ-X800 (KEYENCE, Oasaka, Japan).
106	
107	Results
108	We have established 8 individuals' primary hRPTECs from resected kidneys
109	Table 1 shows the detailed characteristics of 8 individuals who had nephrectomy due to mainly
110	malignancies. 4 individuals have normal kidney function (eGFR > $60 \text{ mL/min}/1.73 \text{ m}^2$, named N-
111	1 to N-4), and the other 4 have mild CKD (eGFR 45-60 mL/min/1.73 m ² , named C-1 to C-4). We
112	established these 8 strains of primary hRPTECs in 2-dimensional cultured condition. Interestingly,

as long as we experienced, lower kidney function did not affect the efficiency of primary cultureestablishment.

115

116 Primary hRPTECs individuals with mild CKD showed relatively elongated morphology, not

117 typical cobblestone appearance as renal epithelia cultured cells

We observed 2-dimensional culture of all the hRPTECs in passage 3 generation. All the hRPTECs became confluent in approximately one week. Cell growth is slightly faster in normal-derived cells. The hRPTECs from individuals with normal kidney function showed cobblestone appearance (Figure 1, the top row). Those from individuals with mild CKD showed relatively elongated

- 122 morphology (**Figure 1**, the bottom row).
- 123

We have succeeded to produce human adult renal tubular organoids, "tubuloids", from different individuals at the same time in a uniform condition.

Next, the hRPTECs were tridimensionalized and made into tubuloids. We seeded hRPTECs on ultra-low adherence plates with 5% FBS in advanced RPMI media. 2 days after seeding, we added Matrigel as the final concentration of it became 10%. We defined day 0 was the day on which Matrigel was added. On day 1, we added

First, we observed the tubuloids on day 4. Normal cell-derived tubuloids immediately began to form a clear, round, bubble-like structure (**Figure 2, the top row**). In contrast, the mild CKD cell-derived tubuloids had a bumpy, small structure (**Figure 2, the bottom row**). Structures of the tubuloids on day 6 showed little change from those on day 4 (**Figure 3**).

On day 13, the difference between normal and mild CKD tubuloids was widened. Normal
 cell-derived tubuloids had beautifully large circular structures (Figure 4, the top row). In contrast,

136	the mild-CKD cell-derived tuberoids showed the small circular structures sporadically (Figure 4,
137	the bottom row). By day 18, the tubuloids with circular structures were even larger. The growth
138	of C-3 was particularly tremendous, greatly exceeding the size of normal cell-derived tubuloids
139	(Figure 5). By day 21, even the C-2 and C-4 tubuloids, which had been difficult to transform into
140	circular tubuloids before, showed a beautiful circular structure as same as tubuloids originated
141	from other individuals (Figure 6).

142 Our observations for 21 days after Matrigel administration revealed that tubuloids derived 143 from normal cells grew faster overall, but with time, even mild CKD cell-derived tubuloids could 144 produce beautifully rounded tubuloids that were comparable to those derived from normal cells.

145

146 **Discussion**

147 Chronic kidney disease (CKD) is a disease composed of a wide variety of underlying causes, and 148 its complexity makes it difficult to study. The additional difficulty is the fact that CKD is an aging 149 and senescence-based diseases, and the most commonly used functional models of CKD are the 150 mouse ones, whose average lifespan is approximately two years, making it difficult to accurately 151 represent the gradual progression of CKD over the decades of human life. Another newly emerging 152 technology, kidney iPSC organoids, are also difficult to represent human aging and senescence 153 because they reflect fetal kidneys, although its sophistication is impressive.

The patient-derived organoids that we have successfully generated are likely to be ideal models for organ research, not only representing the current pathology of the individual, but also providing a true representation of aging and senescence, which is not possible with mice or iPSC organoids. As a case study that has already been reported, it has been found that renal tubular cysts shrink when tolvaptan is used in an adult organoid model of autosomal dominant polysistic kidney

disease (ADPKD), but that tolvaptan does not work in an iPSC organoid-derived model of ADPKD[13].

161 Additionally, tubuloids can be formed by using a completely same protocol. In the case of 162 kidney organoid, a completely same protocol cannot be used for inducing differentiation of iPSCs 163 into nephron progenitor cells [13]. Usually, to compare the different genetic variants by using iPS 164 kidney organoids, we need to use CRISPR/Cas9 system to produce the point mutation on the same 165 iPSCs or embryonic stem cells (ESCs) [14, 15]. By this way, we can induce differentiation of 166 iPSCs into nephron progenitor cells and kidney organoid by using a completely same protocol. 167 Complete comparison between different individuals in a same condition is currently impossible by 168 using iPS kindey organoids. Our tubuloids overcomes this matter. We can produce tubuloids from 169 multiple individuals by using a completely same protocol and compare their response, although 170 their developing phenotypes differ to some extent.

We have also recently succeeded in creating another CKD model by applying cisplatin to patient-derived tubuloids by accelerating cellular senescence [12]. Thus, patient-derived tubuloids as a research model for aging and senescence-based kidneys allow observations that are not possible in disease models such as rodents or iPSC organoids. Kidney tubuloids, which can be easily and rapidly produced in parallel in a same culture condition, are expected to play an active role in further elucidating pathological conditions and identifying new drugs in the future.

177

178 Acknowledgement

We would like to thank the study participants who kindly allowed to give us the pieces of theirresected kidneys.

181

182 Funding

183 This work was supported by Leading Initiative for Excellent Young Researchers (LEADER) from

184 Ministry of Education, Culture, Sports, Science and Technology (to Y.M.), Grant-in-Aid for

185 Research Activity Start-up from Japan Society for the Promotion of Science (to Y.M.), Innovation

186 Idea Contest from Tokyo Medical and Dental University (TMDU) (in 2022 to Y.M. and in 2023

187 to Y.N.), Next Generation Researcher Training Unit from TMDU (to Y.M.) and Priority Research

188 Areas Grant from TMDU (to Y.M.), Research Grant from Uehara Memorial Foundation (to Y.M.),

189 Research Grant (Lifestyle-related diseases) from MSD Life Science Foundation (to Y.M.),

190 Medical Research Grant from Takeda Science Foundation (to Y.M.), and Academic Support from

191 Bayer Yakuhin, Ltd. (to Y.M.).

192

Data availability statements

Further information and requests for resources and reagents should be directed to and will befulfilled by the Lead Contact, Yutaro Mori (y-mori.kid@tmd.ac.jp).

196

197 Author contributions

198 M.M., Y.M. and Y.N. performed the experiments, collected and analyzed data, and wrote the

199 manuscript. Y.M. and M.M. established the hRPTECs and Y.N. and S.M. helped the procedure.

200 T.F., H.K., F.A., K.S., T.M., E.S., and S.U. supported the data analysis. Y.W., S.Y. and Y.F.

- 201 resected the patients' kidneys as standard treatment for malignant diseases. Y.M. developed
- 202 experimental strategy, supervised the project, and edited the manuscript. All authors discussed the
- 203 results and implications and commented on the manuscript.
- 204
- 205 **Disclosure**
- 206 The authors declare that they have no conflicts of interest.
- 207
- 208

209	Table Legends
210	Table 1. Detailed data of the study participants focusing on sex, ages, and renal functions.
211	
212	Figure Legends
213	Figure 1. Primary hRPTECs individuals with mild CKD showed relatively elongated
214	morphology, not typical cobblestone appearance as renal epithelia cultured cells.
215	The top row shows cells from individuals with kidney function (N-1 to N4), and the bottom row
216	shows those from mild CKD (C-1 to C-4). Scale bars : 200µm.
217	
218	Figure 2. On day 4, normal cell-derived tubuloids began to form a clear round bubble-like
219	structure, but the mild CKD cell-derived tubuloids have a structure of bumpy little things.
220	The top row shows 3D-cultured cells from individuals with kidney function (N-1 to N4), and the
221	bottom row shows those from mild CKD (C-1 to C-4). Scale bars : $200\mu m$
222	
223	Figure 3. On day 6, mild CKD cell-derived tubuloids still tended not to form a bubble-like
224	structure.
225	The top row shows 3D-cultured cells from individuals with kidney function (N-1 to N4), and the
226	bottom row shows those from mild CKD (C-1 to C-4). Scale bars : $200\mu m$
227	
228	Figure 4. On day 13, all of normal cell-derived tubuloids formed almost completely, and some
229	of mild CKD cell-derived tubuloids started to form a tubuloids.
230	The top row shows 3D-cultured cells from individuals with kidney function (N-1 to N4), and the
231	bottom row shows those from mild CKD (C-1 to C-4). Scale bars : 200µm

232

233 Figure 5. On day 18, some of mild CKD cell-derived tubuloids became larger, but others not.

- 234 The top row shows 3D-cultured cells from individuals with kidney function (N-1 to N4), and the
- bottom row shows those from mild CKD (C-1 to C-4). Scale bars : 200µm

236

Figure 6. On day 21, all the tubuloids formed complete 3D structure.

- 238 The top row shows 3D-cultured cells from individuals with kidney function (N-1 to N4), and the
- bottom row shows those from mild CKD (C-1 to C-4). Scale bars : 200µm

240

241 **References**

- Rana, N., et al., *GSDMB is increased in IBD and regulates epithelial restitution/repair independent of pyroptosis.* Cell, 2022. **185**(2): p. 283-298 e17.
- Vazquez-Armendariz, A.I. and P.R. Tata, *Recent advances in lung organoid development* and applications in disease modeling. J Clin Invest, 2023. 133(22).
- 246 3. Humphreys, B.D., *Mechanisms of Renal Fibrosis*. Annu Rev Physiol, 2018. **80**: p. 309-326.
- 247 4. O'Sullivan, E.D., J. Hughes, and D.A. Ferenbach, *Renal Aging: Causes and Consequences*.
 248 J Am Soc Nephrol, 2017. 28(2): p. 407-420.
- Morizane, R., et al., *Nephron organoids derived from human pluripotent stem cells model kidney development and injury*. Nat Biotechnol, 2015. 33(11): p. 1193-200.
- Takasato, M., et al., *Kidney organoids from human iPS cells contain multiple lineages and model human nephrogenesis.* Nature, 2015. **526**(7574): p. 564-8.
- Garreta, E., et al., *Fine tuning the extracellular environment accelerates the derivation of kidney organoids from human pluripotent stem cells.* Nat Mater, 2019. 18(4): p. 397-405.
- 8. Bonventre, J.V., *Maladaptive proximal tubule repair: cell cycle arrest*. Nephron Clin Pract, 2014. 127(1-4): p. 61-4.
- 257 9. Chevalier, R.L., *The proximal tubule is the primary target of injury and progression of kidney disease: role of the glomerulotubular junction.* Am J Physiol Renal Physiol, 2016.
 259 311(1): p. F145-61.
- 26010.Mori, Y., et al., KIM-1 mediates fatty acid uptake by renal tubular cells to promote261progressive diabetic kidney disease. Cell Metab, 2021. 33(5): p. 1042-1061 e7.
- Wiraja, C., et al., Nephrotoxicity Assessment with Human Kidney Tubuloids using
 Spherical Nucleic Acid-Based mRNA Nanoflares. Nano Lett, 2021. 21(13): p. 5850-5858.
- 12. Nakao, Y., et al., *Human kidney-derived tubular organoid, tubuloid, recapitulates cellular senescence, inflammation and fibrosis by repeated-cisplatin treatment.* medRxiv, 2024.
 2024.03.17.24304404.
- Little, M.H. and K.T. Lawlor, *Recreating, expanding and using nephron progenitor populations.* Nat Rev Nephrol, 2020. 16(2): p. 75-76.
- Freedman, B.S., et al., *Modelling kidney disease with CRISPR-mutant kidney organoids derived from human pluripotent epiblast spheroids*. Nat Commun, 2015. 6: p. 8715.
- 15. Hiratsuka, K., et al., Organoid-on-a-chip model of human ARPKD reveals mechanosensing
 pathomechanisms for drug discovery. Sci Adv, 2022. 8(38): p. eabq0866.
- Xu, Y., et al., Adult human kidney organoids originate from CD24+ cells and represent
 an advanced model for adult polycystic kidney disease. Nat Genet, 2022. 54(11): p.16901701
- 276

hRPTEC





Figure 1.

Day 4 Tubuloids









Figure 2.

Day 6 Tubuloids









C-2


C-3

0

C-4

Figure 3.

Day 13 Tubuloids








Figure 4.

Day 18 Tubuloids











C-2




C-3




C-4

Figure 5.

Day 21 tubuloids





C-1



C-3

C-4

Figure 6.

Nunber	Sex	Age	Cre(mg/dL)	eGFR (m L/m in/1.73m 2)	BUN(mg/dL)
N -1	M ale	70s	0.79	72.4	9.8
N -2	M ale	40s	0.62	107.1	7.9
N -3	Fam a le	50s	0.77	61.7	12.9
N -4	Fam a le	80s	0.64	66	21.3
C –1	Fam a le	50s	0.92	49.5	12.6
C –2	M ale	60s	1.2	48.8	14.6
C –3	M ale	60s	1.17	50.5	24.1
C –4	Fam ale	50s	0.92	49.2	14.6

Table 1.